147 related articles for article (PubMed ID: 7744702)
21. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
22. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.
Chen JQ; Strand SE; Tennvall J; Lindgren L; Hindorf C; Sjögren HO
J Nucl Med; 1997 Dec; 38(12):1934-9. PubMed ID: 9430473
[TBL] [Abstract][Full Text] [Related]
23. Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody.
Zhang M; Yao Z; Saga T; Sakahara H; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1998 Jan; 39(1):30-3. PubMed ID: 9443734
[TBL] [Abstract][Full Text] [Related]
24. Effect of administration route and dose of streptavidin or biotin on the tumor uptake of radioactivity in intraperitoneal tumor with multistep targeting.
Zhang M; Yao Z; Sakahara H; Saga T; Nakamoto Y; Sato N; Zhao S; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1998 Feb; 25(2):101-5. PubMed ID: 9468023
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin.
Rosebrough SF
Nucl Med Biol; 1993 Jul; 20(5):663-8. PubMed ID: 8358353
[TBL] [Abstract][Full Text] [Related]
26. Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin.
Otsuji E; Yamaguchi T; Matsumura H; Yamamoto K; Tsuruta H; Yata Y; Nishi H; Okamoto K; Kitamura K; Takahashi T
Br J Cancer; 1996 Aug; 74(4):597-602. PubMed ID: 8761376
[TBL] [Abstract][Full Text] [Related]
27. [Application of biotin-avidin system in targeted magnetic resonance imaging].
Liu X; Xu YK; Ye J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1130-2. PubMed ID: 15485783
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the energetics of avidin, streptavidin, neutrAvidin, and anti-biotin antibody binding to biotinylated lipid bilayer examined by second-harmonic generation.
Nguyen TT; Sly KL; Conboy JC
Anal Chem; 2012 Jan; 84(1):201-8. PubMed ID: 22122646
[TBL] [Abstract][Full Text] [Related]
29. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
30. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
[TBL] [Abstract][Full Text] [Related]
31. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.
Marshall D; Pedley RB; Boden JA; Boden R; Melton RG; Begent RH
Br J Cancer; 1996 Mar; 73(5):565-72. PubMed ID: 8605088
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice.
Koizumi M; Endo K; Watanabe Y; Saga T; Sakahara H; Konishi J; Yamamuro T; Toyama S
Cancer Res; 1989 Apr; 49(7):1752-7. PubMed ID: 2924318
[TBL] [Abstract][Full Text] [Related]
33. Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody.
Hnatowich DJ; Fritz B; Virzi F; Mardirossian G; Rusckowski M
Nucl Med Biol; 1993 Feb; 20(2):189-95. PubMed ID: 8448574
[TBL] [Abstract][Full Text] [Related]
34. Disulfide bond-targeted radiolabeling: tumor specificity of a streptavidin-biotinylated monoclonal antibody complex.
del Rosario RB; Wahl RL
Cancer Res; 1990 Feb; 50(3 Suppl):804s-808s. PubMed ID: 2297728
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery.
Arano Y; Wakisaka K; Akizawa H; Ono M; Kawai K; Nakayama M; Sakahara H; Konishi J; Saji H
Bioconjug Chem; 1998; 9(4):497-506. PubMed ID: 9667952
[TBL] [Abstract][Full Text] [Related]
36. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.
Li GP; Zhang H; Zhu CM; Zhang J; Jiang XF
World J Gastroenterol; 2005 Oct; 11(40):6288-94. PubMed ID: 16419157
[TBL] [Abstract][Full Text] [Related]
37. Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody.
Dou S; Virostko J; Greiner DL; Powers AC; Liu G
Mol Pharm; 2015 Aug; 12(8):3097-103. PubMed ID: 26103429
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity of streptavidin-blocked biotinyl-ricin is retrieved by in vitro immunotargeting via biotinyl monoclonal antibody.
Schechter B; Arnon R; Wilchek M
Cancer Res; 1992 Aug; 52(16):4448-52. PubMed ID: 1643636
[TBL] [Abstract][Full Text] [Related]
40. In vivo radiolocalization of antiosteogenic sarcoma monoclonal antibodies in osteogenic sarcoma xenografts.
Nakamura T; Sakahara H; Hosoi S; Yamamuro T; Higashi S; Mikawa H; Endo K; Toyama S
Cancer Res; 1984 May; 44(5):2078-83. PubMed ID: 6585270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
